Olopatadine bests rupatadine for treating chronic idiopathic urticaria, finds study

At the outset of the study, the patients were divided 1:1 to receive orally either olopatadine or rupatadine with a dosing schedule of 10 mg daily for 4 weeks.

Each patient was then assessed for the degree of urticarial pruritus, size of urticarial wheals, number of the urticarial wheals, and number of isolated urticarial episodes. The investigators rated the severity of each symptom on a scale from 1-3, thus allowing for a total composite total symptom score of 12.

On data analysis, the following results were revealed.

· the mean total symptom score for those assigned to olopatadine was 7.58. For those in the rupatadine group, the mean total score was 7.63.

· Serum IgE levels were 347.6 for olopatadine and 284.53 for rupatadine.

· Baseline absolute eosinophil count for the olopatadine and rupatadine groups, respectively, were 683.92 and 672.70.

· The mean reduction in total symptom score for those who had received olopatadine was 3, versus a reduction of 2 in those who received rupatadine.

· Both drugs were well tolerated and presented no new adverse events. The event rate was 20% in olopatadine and 23.07% in rupatadine, with the most common effects between the groups being gastric irritation, drowsiness, headache, and dryness of the mouth.

The team concluded that though both antihistamines are indicated for the treatment of chronic idiopathic urticaria, yet olopatadine demonstrates better clinical improvements and fewer adverse events.

For the full article click on the link: "The Efficiency and Safety of Olopatadine against Rupatadine in Chronic Urticaria of Idiopathic Origin: A Comparative Study

Primary source: Biomedical and Pharmacology Journal